Aerpio Pharmaceuticals Presents Analysis from TIME-2 Study Regarding Effects of AKB-9778 on Renal Function at 2018 Keystone Symposium on Reducing the Burden of Diabetes Related End-Organ Injury

CINCINNATI--(BUSINESS WIRE)--Aerpio Pharmaceuticals, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, announced today that renal function data from the TIME-2 Phase 2a Study of AKB-9778 in the treatment of patients with diabetic macular edema (DME) was presented at the Keystone Symposium on Reducing the Burden of Diabetes Related End-Organ Injury in Santa Fe, New Mexico. The company has previously presented data on improvement of diabetic ret

Full Story →